BLA accepted for review Dupilumab (Regeneron and Sanofi) Interleukin-4 receptor alpha antagonist Treatment of adults with bullous pemphigoid. sBLA accepted for Priority Review Rezpegaldesleukin ...

More than 1,000,000 patients are being treated with Dupixent globally. 1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

Memoirs, interviews and essays now widely celebrate “going no contact” with a parent. The New York Times published this, just a day ago: ”I Broke Up With My Abusive Mother. I Don't Regret ...

TikTok is preparing to sunset its creator marketplace in favor of a new, more expanded experience, the company has informed businesses and creators via email. The online platform, which connects ...

Perspective from John Luo, MD Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management. Now a new study could pave ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid. Bullous pemphigoid ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...

Serializers for solution files, traditional text based .sln file, and XML based .slnx file. Object model for manipulating file contents in common way. SLN File Format Consistent with legacy Visual ...

Our mission is to make the world a safer, more secure and sustainable place. A global leader in applied safety science, UL Solutions transforms safety, security and sustainability challenges into ...